A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Status:
Completed
Trial end date:
2020-05-14
Target enrollment:
Participant gender:
Summary
The reason for this study is to determine the recommended phase 2 dose of the study drug
LY3295668 erbumine in participants with breast cancer that has spread to other parts of the
body.